Please provide your email address to receive an email when new articles are posted on . Treatment with adaptive servo-ventilation for 12 months improved disease-specific quality of life scores. At 12 ...

ORLANDO, Fla. — In a substudy of CAT-HF, patients with HF, sleep-disordered breathing and an implantable cardiac device assigned adaptive servo-ventilation plus optimal medical therapy had a reduction ...

(HealthDay News) — For patients with heart failure with reduced ejection fraction and predominantly central sleep apnea, adaptive servo-ventilation does not improve outcome, according to a study ...

MONTREAL — The treatment of central sleep apnea in heart failure patients was in the spotlight here at CHEST 2015, as experts debated whether or not to completely reject the use of adaptive servo ...

European Respiratory & Pulmonary Diseases, 2016;2(1):Epub ahead of print DOI: http://doi.org/10.17925/ERPD.2016.02.01.1 (Logo: http://photos.prnewswire.com/prnh ...

SAN DIEGO, March 20, 2017 /PRNewswire/ -- ResMed (NYSE:RMD) today announced publication of a study in the Journal of the American College of Cardiology (JACC), which investigated whether treatment of ...

Miami Beach, Fla. (June 11, 2012)—Many chronic heart failure patients struggle with not just strenuous activity but even the essentials such as moderate exercise and normal breathing. Research ...

In research presented at the American Thoracic Society 2024 International Conference, Benjafield and colleagues explored the treatment of sleep-disordered breathing with adaptive sero-ventilation (ASV ...

On May 15, 2015, Respironics, Inc., a Philips business, provided the following response to ResMed's Update on Phase IV SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy in Central Sleep Apnea ...

Central sleep apnea is associated with poor prognosis and death in patients with heart failure. Adaptive servo-ventilation is a therapy that uses a noninvasive ventilator to treat central sleep apnea ...

SAN DIEGO, May 13, 2015 /CNW/ -- ResMed (NYSE: RMD) today announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint. SERVE-HF was ...

To the Editor: Cowie et al. (Sept. 17 issue) 1 report on the results of the Treatment of Sleep-Disordered Breathing with Predominant Central Sleep Apnea by Adaptive Servo Ventilation in Patients with ...